TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03478163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CeFAZolin 1000 MG
Description: Cefazolin 1000 mg every 8 hours for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 900 MG in 6 ML Injection
Description: Clindamycin 900 mg every 8 hours for 3 doses
Study: NCT02715661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: six-month interval of exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: six-month interval of exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: six-month interval of exercise
Study: NCT02185209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Place capsule to mimic antibiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Sandoz
Description: Tablet 500 mg amoxicillin Sandoz three times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Sanofi
Description: 400 mg metronidazole Sanofi administered three times a day (TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Sanofi
Description: 400 mg metronidazole Sanofi administered three times a day (TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenoxymethylpenicillin Meda
Description: 1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
Study: NCT02761746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MESA
Description: MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
Study: NCT00279110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Description: Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
Study: NCT01096355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT04370288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCN (Methylene blue, vitamin C, N-acetyl cysteine)
Description: A mixture of MCN will be injected to covid-19 patients.
Study: NCT00154076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
Study: NCT00698464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Single subcutaneous injection of 600 µg of Pasireotide.
Study: NCT00901030

Intervention type: PROCEDURE
Intervention: Blood drawn
Description: Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
Study: NCT02580396

Intervention type: DEVICE
Group type: OTHER
Intervention: CanADVICE+® (smart phone app)
Description: The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
Study: NCT00786396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy
Description: Daily observation of subjects taking their HIV medications
Study: NCT01521819

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iray
Description: The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Intravitreal injection of Lucentis as needed.
Study: NCT01251120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMARD
Description: Non-biologic DMARDs (including methotrexate) according to current best practice
Study: NCT04197726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sbeIIa/b white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sbeIIa/b white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control white bread
Description: one bread roll containing approximately 75 g of available carbohydrates to be consumed at breakfast
Study: NCT03187977

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training
Description: Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-45 minutes each weekday for 5-9 weeks.
Study: NCT01859078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Administered orally
Study: NCT02785679

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cow's milk formula
Description: addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cow's milk formula
Description: addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
Study: NCT01473316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0980
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Repeating Oral Dose
Study: NCT03367715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: study treatment on Day 1 with one dose of nivolumab 3 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: study treatment on Day 1 with one dose of ipilimumab 1mg/kg

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: total dose of 30 Gy, given in 5 consecutive fractions of 6 Gy each fraction.
Study: NCT04641780

Intervention type: DRUG
Intervention: Brexpiprazole
Description: For the treatment of schizophrenia, the recommended starting dosage for Rexulti™ is 1 mg once daily on Days 1 to 4, taken orally with or without food. The recommended target Rexulti™ dosage is 2 mg to 4 mg once daily. Titrate to 2 mg once daily on Day 5 through Day 7, then to 4 mg on Day 8 based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 4 mg.~The recommended starting dosage for Rexulti™ as adjunctive therapy for MDD is 0.5 mg or 1 mg once daily, taken orally with or without food. Titrate to 1 mg once daily, then up to the target dosage of 2 mg once daily. Dosage increases should occur at weekly intervals based on the patient's clinical response and tolerability. The maximum recommended daily dosage is 3 mg. It must be periodically reassess to determine the continued need and appropriate dosage for treatment.
Study: NCT02708017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided bilateral subcostal TAP block
Description: ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided bilateral posterior TAP block
Description: ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
Study: NCT00294385

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine, Docetaxel
Description: Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
Study: NCT03956368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg
Description: 20mg (every evening orally) for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 20mg (every evening orally) for 8 weeks.
Study: NCT02155036

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) \~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
Study: NCT01037907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pleneva TM BGC20-0134
Description: Placebo or 5 g dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or 5 g dose
Study: NCT00619905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ACZ885
Study: NCT04641507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil versus tamsulosin as MET
Description: 166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil versus tamsulosin as MET
Description: 166 patients with lower ureteric stone will be randomaized using computer-based randomization charts equally into 83 patients (Group A) treatment with tamsulosin 0.4 mg once daily or 83 patients (Group B) treatment with tadalafil 10 mg once daily. Therapy will be given for a maximum of 4 weeks.
Study: NCT01558427

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surveillance
Description: Active clinical surveillance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salvage treatment
Description: Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
Study: NCT02627352

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micropulse Transscleral Cyclophotocoagulation
Description: In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
Study: NCT01772004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Participants received intravenous infusion of Avelumab in dose escalation and expansion cohorts until confirmed progression, unacceptable toxicity, or any reason for withdrawal from the trial or IMP occurs.
Study: NCT01096355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00628108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine 1.25 mg
Description: Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral liquid once a day for two weeks
Study: NCT04687982

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified donor lymphocytes infusion (mDLI)
Description: The planned number of mDLI is 3.~1. Day +50 (+/- 7 days) from allogenic transplant, 1st mDLI 5x105CD3+/kg of recipient.~2. 4-6 weeks after 1st DLI, 2nd mDLI 1x106CD3+/kg of recipient.~3. 4-6 weeks after 2nd DLI, 3rd mDLI 5x106CD3+/kg of recipient.
Study: NCT02052258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Study: NCT01217151

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic monitoring
Description: Hemodynamic monitoring based on the NICOM device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual treatment
Description: Hemodynamic monitoring based on common practice
Study: NCT02019420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate
Description: Tedizolid phosphate IV 200 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Linezolid IV 600 mg twice daily
Study: NCT02294123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 tortillas and white bread
Description: Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 tortillas and white bread
Description: Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 tortillas and white bread
Description: Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
Study: NCT03566433

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tep surgery for inguinal hernia
Description: TEP surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein
Description: Lichtenstein surgery for inguinal hernia
Study: NCT01791023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: 30 minutes of aerobic exercise on treadmill with moderate intensity.
Study: NCT00042406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: HuMax-CD4 80 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered as a subcutaneous infusion twice (BID) with 2 weeks interval followed by administration every 4 weeks up to Week 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humax-CD4
Description: HuMax-CD4 160 mg was administered as a subcutaneous infusion BID with 2 weeks interval followed by administration every 4 weeks up to Week 22.
Study: NCT00531882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 30 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 40 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
Study: NCT04009850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cigarette Brand Switching
Description: Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette Flavor
Description: Adult smokers will be provided with either menthol or tobacco flavored e-cigarettes in addition to the non-menthol cigarettes
Study: NCT00002920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: medroxyprogesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Study: NCT01965639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension of Care
Description: Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.